Today: 9 June 2026
Browse Category

NASDAQ:AKAM 15 December 2025 - 19 May 2026

Nasdaq slips as Wall Street rally faces yield jolt

Nasdaq slips as Wall Street rally faces yield jolt

U.S. stocks fell Tuesday morning, with the Nasdaq down 1.05% and the S&P 500 off 0.69%, as rising Treasury yields and firm oil prices pressured markets. The U.S. 10-year yield neared 4.61%, while Brent crude traded at $110.67 a barrel. Materials and consumer discretionary sectors led declines. Investors await Nvidia’s earnings and Federal Reserve minutes due Wednesday.
19 May 2026
······
Biggest Stock Movers Today: Fervo, Nebius and Ford Surge as Wix Sinks on AI Spending Shock

Biggest Stock Movers Today: Fervo, Nebius and Ford Surge as Wix Sinks on AI Spending Shock

Fervo Energy surged 33% in its Nasdaq debut, raising $1.89 billion and reaching a $10.21 billion valuation. Nebius, Ford, Akamai, and Wolfspeed climbed as investors sought AI-infrastructure stocks. Wix and Dynatrace fell after earnings. Producer prices jumped 1.4% in April, the biggest monthly rise in four years, while rate-cut expectations for 2026 dropped.
13 May 2026
·····
US Stock Market Today: S&P 500, Nasdaq Hit Records as Jobs Surprise Keeps Wall Street Rally Alive

US Stock Market Today: S&P 500, Nasdaq Hit Records as Jobs Surprise Keeps Wall Street Rally Alive

The S&P 500 and Nasdaq reached record highs midday Friday, lifted by stronger-than-expected April jobs data and gains in Nvidia and Apple. Nonfarm payrolls rose by 115,000 last month while unemployment held at 4.3%. Brent crude traded at $101.65, and the 10-year Treasury yield stood at 4.346%. U.S. consumer sentiment fell to a record low, according to the University of Michigan.
8 May 2026
····
Akamai Stock Set to Jump as $1.8 Billion AI Cloud Deal Steals the Earnings Spotlight

Akamai Stock Set to Jump as $1.8 Billion AI Cloud Deal Steals the Earnings Spotlight

Akamai Technologies shares jumped 26% in premarket trading after announcing a $1.8 billion, seven-year cloud infrastructure deal with an unnamed U.S. AI model developer. First-quarter revenue rose 6% to $1.074 billion, with cloud infrastructure services up 40% to $95 million. The company forecast softer second-quarter results, with revenue and adjusted earnings below analyst estimates.
8 May 2026
···
Akamai Stock Is Jumping Before Earnings: The API Security Bet Investors Are Watching

Akamai Stock Is Jumping Before Earnings: The API Security Bet Investors Are Watching

Akamai shares jumped about 10% Tuesday after launching new API security tools ahead of its first-quarter earnings report, with the stock near $116 and a market value of $16.8 billion. The company said its Security Posture Center will help firms measure and control API risks as incidents tied to AI rise. Cloudflare and Fastly also saw double-digit gains. Akamai’s earnings call is set for Thursday at 4:30 p.m. ET.
5 May 2026
····
Akamai stock holds near $105 after 10% pop as Fastly’s results jolt the edge trade

Akamai stock holds near $105 after 10% pop as Fastly’s results jolt the edge trade

Akamai shares held steady in premarket trading Friday after jumping 10.35% to $104.61 on Thursday, following Fastly’s upbeat forecast and AI-driven traffic commentary. Investors are awaiting Akamai’s fourth-quarter results and guidance, due Feb. 19, with Wall Street expecting earnings of $1.75 per share on $1.08 billion in revenue.
13 February 2026
····
Cloud computing stocks face Tuesday test after Trump tariff threat rattles big tech

Cloud computing stocks face Tuesday test after Trump tariff threat rattles big tech

Cloud-focused ETFs fell Friday, with CLOU down 1.34% to $21.34, WCLD off 2.05%, and SKYY losing 0.9%, after U.S. tariff threats and declines in European tech stocks. Nasdaq 100 futures dropped as U.S. markets stayed closed for Martin Luther King Jr. Day. Microsoft reports earnings Jan. 28, Alphabet on Feb. 4. Investors await updates on cloud demand and spending.
19 January 2026
········
Cloud computing stocks ETF CLOU slips into weekend — what Wall Street watches next

Cloud computing stocks ETF CLOU slips into weekend — what Wall Street watches next

Cloud computing stocks, tracked by the Global X Cloud Computing ETF (CLOU), slipped 0.27% to $22.58 Friday, underperforming the S&P 500, which closed at a record high. Investors are cautious ahead of February earnings and the Fed’s late-January meeting, with tariff news also looming. The U.S. jobs report showed payrolls rose by 50,000 in December, while the unemployment rate fell to 4.4%.
10 January 2026
·······
Cloud computing stocks slide into 2026 as yields rise — what CLOU ETF investors watch next

Cloud computing stocks slide into 2026 as yields rise — what CLOU ETF investors watch next

The Global X Cloud Computing ETF (CLOU) dropped 2.34% to $22.09 on Friday, underperforming as Treasury yields rose and investors rotated out of high-valuation tech. Other cloud ETFs also fell. The move comes ahead of the U.S. December jobs report and the Federal Reserve’s late-January meeting, both seen as key for rate-sensitive sectors.
4 January 2026
·······
Akamai Technologies (AKAM) Stock Jumps After KeyBanc Double Upgrade to Overweight and $115 Target — Edge Compute Momentum Takes Center Stage (Dec. 15, 2025)

Akamai Technologies (AKAM) Stock Jumps After KeyBanc Double Upgrade to Overweight and $115 Target — Edge Compute Momentum Takes Center Stage (Dec. 15, 2025)

Akamai shares rose about 4% to $89.33 intraday Monday after KeyBanc double-upgraded the stock to Overweight and raised its price target to $115, citing accelerating revenue from compute and AI-related services. The firm highlighted Akamai’s NVIDIA GPU partnership and shifting business mix, with Q3 cloud infrastructure revenue up 39% year over year.
15 December 2025
·

Stock Market Today

  • Nuvalent Shares Surge Near $124 Following GSK's $10.6 Billion Buyout Offer
    June 9, 2026, 10:35 AM EDT. Nuvalent's stock jumped 38.9% to $122.93 after GSK announced a $10.6 billion cash acquisition at $124 per share, reflecting a 40% premium to the last close. The deal highlights GSK's strategic move to expand its oncology portfolio beyond its current 6% share of sales, aiming to capitalize on Nuvalent's two lung cancer drugs pending FDA decisions this year. The tender offer needs the approval of at least half of Nuvalent's Class A shares and U.S. antitrust clearance. Early analyst reactions included target price adjustments but echoed caution over valuation. Nuvalent's pipeline products could face competition from existing ALK-targeted therapies by Pfizer and Roche.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Go toTop